Skip to main content
Premium Trial:

Request an Annual Quote

The BioCommerce Week Index: Mar 24, 2005

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(March 22, 2005)
Last Price
(
March 15, 2005)
% Change
Agilent
A
22.58
23.26
-2.92
Applied Biosystems
ABI
20.36
20.34
0.10
BD
BDX
58.62
58.85
-0.39
Beckman
BEC
68.90
70.78
-2.66
Bio-Rad
BIO
48.00
47.83
0.36
Bruker
BRKR
3.26
3.95
-17.47
GE
GE
35.50
36.00
-1.39
Harvard Bio
HBIO
4.08
3.95
3.29
Invitrogen
IVGN
71.31
71.40
-0.13
Molecular Devices
MDCC
18.98
18.76
1.17
PerkinElmer
PKI
21.00
21.90
-4.11
Sigma
SIAL
62.07
63.00
-1.48
Stratagene
STGN
8.05
8.00
0.63
Thermo
TMO
25.33
27.45
-7.72
Waters
WAT
46.67
47.85
-2.47
Index Average
34.31
34.89
-1.65

 

Bruker Shares Tumble After 10-K Filing Extension Request

Bruker shares lost 17 percent in the five-day period ending Tuesday and the BioCommerce Week Index finished down for a second consecutive week.

Bruker lost 17 percent of its market capitalization, or $61 million, after announcing last week that it would request an extension of the deadline for filing its 10-K report. The company said it would restate its net loss between $0.07 and $0.09 a share from its previously reported $0.06 a share after finding a "material weakness" in its internal controls at one of its subsidiaries.

Bruker's market cap was $291 million as of market close Tuesday.

Harvard Bio shares gained 3.3 percent on the week, ending a string of five straight weeks of losses, to lead five companies whose shares finished up. Seven companies' shares lost ground as Thermo Electron dropped 7.7 percent, PerkinElmer fell 4 percent, and Agilent dropped 3 percent.

Overall, the Index closed at $34.89 for the five-day period, down 1.65 percent from last week. The Index has closed down for two consecutive weeks and has been down for four of the last six weeks since reaching a high of $36.10 on Feb. 8.

For the week, the Index outperformed the S&P 500 and the Nasdaq, which fell 2 percent, and the Dow Jones, which dropped 2.3 percent. The Amex biotech index was down 0.5 percent while the Amex pharma index fell 1.7 percent.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.